CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise.
Precision Autoimmune Therapeutics is a clinical-stage innovative drug development company focused on precision therapeutics for patients with autoimmune and inflammatory diseases.
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
Miikana Therapeutics is a private held biotechnology company. It is a biopharmaceutical company focuses on the discovery and development of medicines for the treatment of cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.